Comparative efficacy and safety of everolimus-eluting bioresorbable scaffold versus everolimus-eluting metallic stents: A systematic review and meta-analysis

Annals of Internal Medicine

Volumn 164, Issue 11, 2016, Pages 752-763

  Zhang, Xin Lin ^a   Zhu, Li ^a   Wei, Zhong Hai ^a   Zhu, Qing Qing ^a   Qiao, Jian Zhong ^a   Dai, Qing ^a   Huang, Wei ^a   Li, Xiao Hong ^a   Xie, Jun ^a   Kang, Li Na ^a   Wang, Lian ^a   Xu, Biao ^a  

^a MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

EVEROLIMUS; CARDIOVASCULAR AGENT;

CLINICAL EFFECTIVENESS; COCHRANE LIBRARY; CORONARY ARTERY DISEASE; DEVICE SAFETY; EMBASE; EVEROLIMUS ELUTING BIORESORBABLE SCAFFOLD STENT; EVEROLIMUS ELUTING CORONARY STENT; EVEROLIMUS ELUTING METALLIC STENT; HEART DEATH; HEART INFARCTION; HUMAN; INCIDENCE; MEDLINE; META ANALYSIS; OBSERVATIONAL STUDY; PERCUTANEOUS CORONARY INTERVENTION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVASCULARIZATION; REVIEW; STENT THROMBOSIS; SYSTEMATIC REVIEW; ADVERSE EFFECTS; BIODEGRADABLE IMPLANT; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS; DEVICES; DRUG ELUTING STENT; MORTALITY; MYOCARDIAL INFARCTION; POSTOPERATIVE COMPLICATION; THROMBOSIS; TISSUE SCAFFOLD;

ABSORBABLE IMPLANTS; CARDIOVASCULAR AGENTS; CAUSE OF DEATH; COMPARATIVE EFFECTIVENESS RESEARCH; CORONARY ARTERY DISEASE; DRUG-ELUTING STENTS; EVEROLIMUS; HUMANS; MYOCARDIAL INFARCTION; PERCUTANEOUS CORONARY INTERVENTION; POSTOPERATIVE COMPLICATIONS; THROMBOSIS; TISSUE SCAFFOLDS;

EID: 84973442115     PISSN: 00034819     EISSN: 15393704     Source Type: Journal    
DOI: 10.7326/M16-0006     Document Type: Review

References (81)

1. Fischman DL, Leon MB, Baim DS, Schatz RA, Savage MP, Penn I, et al. A randomized comparison of coronary-stent placement and balloon angioplasty in the treatment of coronary artery disease. Stent Restenosis Study Investigators. N Engl J Med. 1994;331:496-501. [PMID: 8041414].
2. Nakazawa G, Finn AV, Joner M, Ladich E, Kutys R, Mont EK, et al. Delayed arterial healing and increased late stent thrombosis at culprit sites after drug-eluting stent placement for acute myocardial infarction patients: An autopsy study. Circulation. 2008;118:1138-45. [PMID: 18725485] doi:10.1161/CIRCULATIONAHA.107.762047.
3. Bittl JA. Bioresorbable stents: The next revolution [Editorial]. Circulation. 2010;122:2236-8. [PMID: 21098438] doi:10.1161/CIRCULATIONAHA.110.988469.
4. Wiebe J, Nef HM, Hamm CW. Current status of bioresorbable scaffolds in the treatment of coronary artery disease. J Am Coll Cardiol. 2014;64:2541-51. [PMID: 25500240] doi:10.1016/j.jacc.2014.09.041.
5. Serruys PW, Ormiston JA, Onuma Y, Regar E, Gonzalo N, Garcia- Garcia HM, et al. A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet. 2009;373:897-910. [PMID: 19286089] doi:10.1016/S0140-6736(09)60325-1.
6. Gogas BD, Serruys PW, Diletti R, Farooq V, Brugaletta S, Radu MD, et al. Vascular response of the segments adjacent to the proximal and distal edges of the ABSORB everolimus-eluting bioresorbable vascular scaffold: 6-month and 1-year follow-up assessment: A virtual histology intravascular ultrasound study from the first-in-man ABSORB cohort B trial. JACC Cardiovasc Interv. 2012;5:656-65. [PMID: 22721662] doi:10.1016/j.jcin.2012.02.017.
7. Nakatani S, Onuma Y, Ishibashi Y, Muramatsu T, Iqbal J, Zhang YJ, et al. Early (before 6 months), late (6-12 months) and very late (after 12 months) angiographic scaffold restenosis in the ABSORB Cohort B trial. EuroIntervention. 2015;10:1288-98. [PMID: 24572936] doi:10.4244/EIJV10I11A218.
8. Di Mario C, Caiazzo G. Biodegradable stents: The golden future of angioplasty? Lancet. 2015;385:10-2. [PMID: 25230592] doi:10.1016/S0140-6736(14)61636-6.
9. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. Ann Intern Med. 2009;151:264-9. [PMID: 19622511] doi:10.7326/0003-4819-151-4-200908180-00135.
10. Cutlip DE, Windecker S, Mehran R, Boam A, Cohen DJ, van Es GA, et al; Academic Research Consortium. Clinical end points in coronary stent trials: A case for standardized definitions. Circulation. 2007;115:2344-51. [PMID: 17470709].
11. Higgins JPT, Altman DG, Sterne JAC. Assessing risk of bias in included studies. In: Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Version 5.1.0 [updated March 2011]. The Cochrane Collaboration; 2011. Accessed at www.cochrane.org/resources/handbookon 15 December 2015.
12. Wells GA, Shea B, O'Connell D, Peterson J, Welch V, Losos M, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa, Ontario, Canada: Ottawa Hospital Research Institute; 2013. Accessed at www.ohri.ca/programs/clinical-epidemiology/oxford.asp on 15 December 2015.
13. Freeman MF, Tukey JW. Transformations related to the angular and the square root. The Annals of Mathematical Statistics. 1950;21: 607-11.
14. Cornell JE, Mulrow CD, Localio R, Stack CB, Meibohm AR, Guallar E, et al. Random-effects meta-analysis of inconsistent effects: A time for change. Ann Intern Med. 2014;160:267-70. [PMID: 24727843] doi:10.7326/M13-2886.
15. Sweeting MJ, Sutton AJ, Lambert PC. What to add to nothing? Use and avoidance of continuity corrections in meta-analysis of sparse data. Stat Med. 2004;23:1351-75. [PMID: 15116347].
16. Serruys PW, Chevalier B, Dudek D, Cequier A, Carrié D, Iniguez A, et al. A bioresorbable everolimus-eluting scaffold versus a metallic everolimus-eluting stent for ischaemic heart disease caused by denovo native coronary artery lesions (ABSORB II): An interim 1-year analysis of clinical and procedural secondary outcomes from a randomised controlled trial. Lancet. 2015;385:43-54. [PMID: 25230593] doi:10.1016/S0140-6736(14)61455-0.
17. Puricel S, Arroyo D, Corpataux N, Baeriswyl G, Lehmann S, Kallinikou Z, et al. Comparison of everolimus- And biolimus-eluting coronary stents with everolimus-eluting bioresorbable vascular scaffolds. J Am Coll Cardiol. 2015;65:791-801. [PMID: 25720622] doi:10.1016/j.jacc.2014.12.017.
18. Sabaté M, Windecker S, Iñiguez A, Okkels-Jensen L, Cequier A, Brugaletta S, et al. Everolimus-eluting bioresorbable stent vs. durable polymer everolimus-eluting metallic stent in patients with STsegment elevation myocardial infarction: results of the randomized ABSORB ST-segment elevation myocardial infarction-TROFI II trial. Eur Heart J. 2016;37:229-40. [PMID: 26405232] doi:10.1093/eurheartj/ehv500.
19. Ellis SG, Kereiakes DJ, Metzger DC, Caputo RP, Rizik DG, Teirstein PS, et al; ABSORB III Investigators. Everolimus-eluting bioresorbable scaffolds for coronary artery disease. N Engl J Med. 2015;373:1905-15. [PMID: 26457558] doi:10.1056/NEJMoa1509038.
20. Gao R, Yang Y, Han Y, Huo Y, Chen J, Yu B, et al; ABSORB China Investigators. Bioresorbable vascular scaffolds versus metallic stents in patients with coronary artery disease: ABSORB China Trial. J Am Coll Cardiol. 2015;66:2298-309. [PMID: 26471805] doi:10.1016/j.jacc.2015.09.054.
21. Kimura T, Kozuma K, Tanabe K, Nakamura S, Yamane M, Muramatsu T, et al; ABSORB Japan Investigators. A randomized trial evaluating everolimus-eluting Absorb bioresorbable scaffolds vs. everolimus-eluting metallic stents in patients with coronary artery disease: ABSORB Japan. Eur Heart J. 2015;36:3332-42. [PMID: 26330419] doi:10.1093/eurheartj/ehv435.
22. Abizaid A. ABSORB Extend: 1-year results in moderately complex lesions. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/ABSORB-Extend-1-year-results-in-moderately-complex-lesions on 18 December 2015.
23. Brugaletta S, Gori T, Low AF, Tousek P, Pinar E, Gomez-Lara J, et al. Absorb bioresorbable vascular scaffold versus everolimuseluting metallic stent in ST-segment elevation myocardial infarction: 1-year results of a propensity score matching comparison: The BVSEXAMINATION Study (Bioresorbable Vascular Scaffold-A Clinical Evaluation of Everolimus Eluting Coronary Stents in the Treatment of Patients with ST-segment Elevation Myocardial Infarction). JACC Cardiovasc Interv. 2015;8:189-97. [PMID: 25616924] doi:10.1016/j.jcin.2014.10.005.
24. Costopoulos C, Latib A, Naganuma T, Miyazaki T, Sato K, Figini F, et al. Comparison of early clinical outcomes between ABSORB bioresorbable vascular scaffold and everolimus-eluting stent implantation in a real-world population. Catheter Cardiovasc Interv. 2015; 85:E10-5. [PMID: 24909303] doi:10.1002/ccd.25569.
25. Cortese B, Ielasi A, Romagnoli E, Varricchio A, Cuculo A, Loi B, et al. Clinical comparison with short-term follow-up of bioresorbable vascular scaffold versus everolimus-eluting stent in primary percutaneous coronary interventions. Am J Cardiol. 2015;116:705-10. [PMID: 26100584] doi:10.1016/j.amjcard.2015.05.049.
26. Onuma Y, Felix C, Ishibashi Y, Diletti R, Karanasos A, Regar E, et al. Six-month clinical outcomes after implantation of an everolimus-eluting bioresorbable scaffold or an everolimus-eluting metallic stent in complex lesions: A propensity matched comparison [Abstract]. Presented at the European Society of Cardiology (ESC) Congress 2014, Barcelona, Spain, 30 August-3 September 2014. Abstract no. P5478. Eur Heart J. 2014;35(Suppl 1):982-3.
27. Gori T, Schulz E, Hink U, Jabs A, Wenzel P, Munzel T. Implantation of ABSORB everolimus-eluting bioresorbable vascular scaffolds in the setting of ACS patients. Presented at EuroPCR, Paris, France, 21-24 May 2013. Accessed at www.pcronline.com/Lectures/2013/Implantation-of-ABSORB-everolimus-eluting-bioresorbable-vascular-scaffolds-in-the-setting-of-ACS-patients on 18 December 2015.
28. Ormiston JA, Serruys PW, Onuma Y, van Geuns RJ, de Bruyne B, Dudek D, et al. First serial assessment at 6 months and 2 years of the second generation of Absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study. Circ Cardiovasc Interv. 2012;5:620-32.[PMID:23048057]doi:10.1161/CIRCINTERVENTIONS.112.971549.
29. Eeckhout E. ABSORB First: worldwide all-comer 1-year outcomes. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/ABSORB-First-worldwide-all-comer-1-year-outcomes on 18 December 2015.
30. Kraak RP, Hassell ME, Grundeken MJ, Koch KT, Henriques JP, Piek JJ, et al. Initial experience and clinical evaluation of the Absorb bioresorbable vascular scaffold (BVS) in real-world practice: The AMC Single Centre Real World PCI Registry. EuroIntervention. 2015;10: 1160-8. [PMID: 25136885] doi:10.4244/EIJY14M08-08.
31. Wöhrle J, Naber C, Schmitz T, Schwencke C, Frey N, Butter C, et al. Beyond the early stages: insights from the ASSURE registry on bioresorbable vascular scaffolds. EuroIntervention. 2015;11:149-56. [PMID: 25499836] doi:10.4244/EIJY14M12-10.
32. Azzalini L, L'Allier PL. Bioresorbable vascular scaffold thrombosis in an all-comer patient population: single-center experience. J Invasive Cardiol. 2015;27:85-92. [PMID: 25661759].
33. Diletti R, Karanasos A, Muramatsu T, Nakatani S, Van Mieghem NM, Onuma Y, et al. Everolimus-eluting bioresorbable vascular scaffolds for treatment of patients presenting with ST-segment elevation myocardial infarction: BVS STEMI first study. Eur Heart J. 2014;35: 777-86. [PMID: 24394380] doi:10.1093/eurheartj/eht546.
34. Camacho FSJ, Roa GJ, Cardenal PR, Gómez MAE, Ramzy AM, Gómez FP, et al. Clinical outcomes of patients with long lesions treated with everolimus-eluting bioresorbable vascular scaffolds: A subgroup analysis from a single-centre all-comers Absorb registry [Abstract]. Presented at EuroPCR, Paris, France, 19-22 May 2015. Abstract no. Euro15A-POS043. Accessed at www.pcronline.com/eurointervention/AbstractsEuroPCR2015/abstracts-europcr-2015/POS043/clinical-outcomes-of-patients-with-long-lesions-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds-a-subgroup-analysis-from-a-single-centre-all-comers-absorb-registry.htmlon 18 December 2015.
35. Costopoulos C, Crowson MC, Brown AJ, Braganza DM, Bennett MR, Hoole SP, et al. Mid-term clinical outcomes of ABSORB bioresorbable vascular scaffold implantation in a real-world population: A single-center experience. Cardiovasc Revasc Med. 2015;16:461-4. [PMID: 26440767] doi:10.1016/j.carrev.2015.08.003.
36. Cuculi F. A novel approach to treat in-stent restenosis: 6-month results using the Absorb bioresorbable scaffolds. Presented at Euro- PCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/A-novel-approach-to-treat-in-stent-restenosis-6-month-results-using-the-Absorb-bioresorbable-scaffolds on 18 December 2015.
37. Dalos D, Moser F, Gangl C, Roth C, Krenn L, Scherzer S, et al. Early outcomes of real-world patients treated with everolimuseluting bioresorbable vascular scaffolds [Abstract]. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/eurointervention/AbstractsAsiaPCR2015-issue/abstracts-asiapcr-2015/19/early-outcomes-of-real-world-patients-treated-with-everolimus-eluting-bioresorbable-vascular-scaffolds.htmlon 18 December 2015.
38. De Waha S, El-Mawardy M, Sato T, Sulimov D, Toelg R, Abdel- Wahab M, et al. Safety and efficacy of everolimus-eluting bioresorbable scaffolds in complex coronary lesions [Abstract]. Presented at EuroPCR, Paris, France, 19-22 May 2015. Abstract no. Euro15APOS042. Accessed at www.pcronline.com/eurointervention/AbstractsEuroPCR2015/abstracts-europcr-2015/POS042/safety-and-efficacy-of-everolimus-eluting-bioresorbable-scaffolds-in-complex-coronary-lesions.html on 18 December 2015.
39. El Khoury R, Naim C, Noiseux N, Kokis A, Gobeil F, Mansour S. Acute and mid-term clinical outcomes of the everolimus-eluting bioresorbable vascular scaffolds in an all-comer cohort [Abstract]. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2014, Washington, DC, 13-17 September 2014. Abstract no. TCT-635. J Am Coll Cardiol. 2014;64:B185. doi:10.1016/j.jacc.2014.07.699.
40. Elabbassi W. Bioresorbable scaffold is associated with a low rate of coronary events in an all-comer population in the Middle East. Presented at EuroPCR, Paris, France, 20-23 May 2014. Accessed at www.pcronline.com/Lectures/2014/Bioresorbable-scaffold-is-associated-with-a-low-rate-of-coronary-events-in-an-all-comer-population-in-the-Middle-Easton 18 December 2015.
41. Robaei D, Back L, Ooi SY, Pitney M, Jepson N. Twelve-month outcomes with a bioresorbable everolimus-eluting scaffold: results of the ESHC-BVS registry at two Australian centers. J Invasive Cardiol. 2015. [PMID: 26567454].
42. Hamm C. GABI-R: Acute performance from German-Austrian real-world experience. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/GABI-R-acute-performance-from-German-Austrian-real-world-experience on 18 December 2015.
43. Haji K, Dick R, Baker L, Waugh S. Bioresorbable scaffold stents, single centre experience. Heart Lung Circ. 2015;24:S264-S265.
44. Hoppmann P, Kufner S, Cassese S, Wiebe J, Schneider S, Pinieck S, et al. Angiographic and clinical outcomes of patients treated with everolimus-eluting bioresorbable stents in routine clinical practice: results of the ISAR-ABSORB registry. Catheter Cardiovasc Interv. 2015. [PMID: 26708019] doi:10.1002/ccd.26346.
45. Jaguszewski M, Ghadri JR, Zipponi M, Bataiosu DR, Diekmann J, Geyer V, et al. Feasibility of second-generation bioresorbable vascular scaffold implantation in complex anatomical and clinical scenarios. Clin Res Cardiol. 2015;104:124-35. [PMID: 25173111] doi:10.1007/s00392-014-0757-4.
46. Kabir CMS, Khan SR, Banerjee S. Immediate and midterm outcomes following transradial PCI with bioresorbable vascular scaffold in diabetic patients: single center registry in Bangladesh. Indian Heart J. 2015;67:S49-S50. doi:10.1016/j.ihj.2015.10.118.
47. Khripun A, Malevannyi M, Kulikovskikh Y. Short- And midterm outcomes of PCI with bioresorbable vascular scaffolds for STEMI treatment [Abstract]. Presented at EuroPCR, Paris, France, 19-22 May 2015. Abstract no. Euro15A-MA030. Accessed at www.pcronline.com/eurointervention/AbstractsEuroPCR2015/abstracts-europcr-2015/MA030/short-and-midterm-outcomes-of-pci-with-bioresorbable-vascular-scaffolds-for-stemi-treatment.html on 18 December 2015.
48. Vlachojannis GJ, Royaards KJ, Koper MA, Boxma-De KBM, Kraaijeveld AO, Wassing J, et al. Five-year experience with the Absorb bioresorbable vascular scaffold: The Maasstad Absorb registry [Abstract]. Presented at EuroPCR, Paris, France, 19-22 May 2015. Abstract no. Euro15A-MA030. Accessed at www.pcronline.com/eurointervention/AbstractsEuroPCR2015/abstracts-europcr-2015/POS059/five-year-experience-with-the-absorb-bioresorbable-vascular-scaffold-the-maasstad-absorb-registry.html on 18 December 2015.
49. Markovic S, Hallaschka S, Kunze M, Dahme T, Bernhardt P, Walcher D, et al. Clinical follow-up after implantation of bioresorbable everolimus-eluting scaffolds-a single-centre registry with quantitative coronary [Abstract]. Presented at EuroPCR, Paris, France, 20-23 May 2014. Abstract no. Euro14A-POS044. Accessed at www.pcronline.com/eurointervention/AbstractsEuroPCR2014/europcr-abstracts-and-posters-2014/044/clinical-follow-up-after-implantation-of-bioresorbable-everolimus-eluting-scaffolds-a-single-centre-registry-with-quantitative-coronary-analysis.html on 18 December 2015.
50. Moscarella E, Varricchio A, Stabile E, Latib A, Ielasi A, Tespili M, et al. Bioresorbable vascular scaffold implantation for the treatment of coronary in-stent restenosis: results from a multicenter Italian ex-perience. Int J Cardiol. 2015;199:366-72. [PMID: 26241643] doi:10.1016/j.ijcard.2015.07.002.
51. Dudek D. Bioresorbable vascular scaffolds in patients with ACS- The multicentre registry in Poland POLAR ACS. Presented at Euro- PCR, Paris, France, 20-23 May 2014. Accessed at www.pcronline.com/Lectures/2013/Bioresorbable-vascular-scaffolds-in-patients-with-ACS-The-multicentre-registry-in-Poland-POLAR-ACS on 18 December 2015.
52. Widimsky P, Petr R, Tousek P, Maly M, Linkova H, Vrana J, et al. One-year clinical and computed tomography angiographic outcomes after bioresorbable vascular scaffold implantation during primary percutaneous coronary intervention for ST-segment-elevation myocardial infarction: The PRAGUE-19 Study. Circ Cardiovasc Interv. 2015;8. [PMID: 26628591] doi:10.1161/CIRCINTERVENTIONS.115.002933.
53. Hernández FH. REPARA: Acute performance from Iberian realworld experience. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/REPARA-acute-performance-from-Iberian-real-world-experience on 18 December 2015.
54. Romero M, Suarez DLJ, Martin P, Garcia J, Pan M, Mazuelos F, et al. Bioresorbable vascular scaffolding for the percutaneous treatment of long diffuse coronary lesions. Eur Heart J. 2015;36:649.
55. Sainsous J, Brunet J, Bayet G, Hager FX, Dufaitre G, Meille L, et al. Bioresorbable everolimus eluting stents in acute coronary syndromes. Preliminary implantation data and follow up of 40 patients. Arch Cardiovasc Dis. 2015;7:134. doi:10.1016/S1878-6480(15)30011-2.
56. Seeger J, Marcovic S, Gonska B, Walcher D, Rottbauer W, Wöhrle J. Clinical follow-up after implantation of bioresorbable drug-eluting scaffolds: A prospective single center experience up to 3 years [Abstract]. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2015, San Francisco, California, 11-15 October 2015. Abstract no. TCT-509. J Am Coll Cardiol. 2015;66: B208. doi:10.1016/j.jacc.2015.08.526.
57. Suarez De Lezo J. Immediate results and 1-year follow-up of patients with bifurcation coronary lesions treated with everolimuseluting bioabsorbable scaffold. Presented at EuroPCR, Paris, France, 19-22 May 2015. Accessed at www.pcronline.com/Lectures/2015/Immediate-results-and-1-year-follow-up-of-patients-with-bifurcation-coronary-lesions-treated-with-everolimus-eluting-bioabsorbable-scaffold on 18 December 2015.
58. Teeuwen K, Hubbers S, Tijssen JGP, Van Der Heyden JAS, Rensing BJWM, Suttorp MJ. Experiences with the Absorb everolimuseluting bioresorbable vascular scaffold in all comers: The St. Antonius hospital single centre registry. Clin Trials Regul Sci Cardiol. 2015;10: 1-6. doi:10.1016/j.ctrsc.2015.09.004.
59. Wójcik J, Madejczyk A, Wiórkowski K, Jankiewicz M. Bioresorbable scaffold as option for the treatment of coronary in-stent restenosis: result from single-centre prospective observational study with angiographic follow-up [Abstract]. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2015, San Francisco, California, 11-15 October 2015. Abstract no. TCT-504. J Am Coll Cardiol. 2015;66:B206.
60. Gori T, Schulz E, Hink U, Kress M, Weiers N, Weissner M, et al. Clinical, angiographic, functional, and imaging outcomes 12 months after implantation of drug-eluting bioresorbable vascular scaffolds in acute coronary syndromes. JACC Cardiovasc Interv. 2015;8:770-7. [PMID: 25999097] doi:10.1016/j.jcin.2014.12.244.
61. Van Geuns RJ. BVS Expand: 6-month results. Presented at Euro- PCR, Paris, France, 20-23 May 2014. Accessed at www.pcronline.com/Lectures/2014/BVS-Expand-6-month-results on 18 December 2015.
62. Capodanno D, Gori T, Nef H, Latib A, Mehilli J, Lesiak M, et al. Percutaneous coronary intervention with everolimus-eluting bioresorbable vascular scaffolds in routine clinical practice: early and midterm outcomes from the European multicentre GHOST-EU registry. EuroIntervention. 2015;10:1144-53. [PMID: 25042421] doi:10.4244/EIJY14M07-11.
63. Muramatsu T, Onuma Y, van Geuns RJ, Chevalier B, Patel TM, Seth A, et al; ABSORB Cohort B Investigators. 1-year clinical outcomes of diabetic patients treated with everolimus-eluting bioresorbable vascular scaffolds: A pooled analysis of the ABSORB and the SPIRIT trials. JACC Cardiovasc Interv. 2014;7:482-93. [PMID: 24746650] doi:10.1016/j.jcin.2014.01.155.
64. Bangalore S, Toklu B, Amoroso N, Fusaro M, Kumar S, Hannan EL, et al. Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ. 2013;347: f6625. [PMID: 24212107] doi:10.1136/bmj.f6625.
65. Bangalore S, Kumar S, Fusaro M, Amoroso N, Attubato MJ, Feit F, et al. Short- And long-term outcomes with drug-eluting and baremetal coronary stents: A mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation. 2012;125:2873-91. [PMID: 22586281] doi:10.1161/CIRCULATIONAHA.112.097014.
66. Bangalore S, Kumar S, Fusaro M, Amoroso N, Kirtane AJ, Byrne RA, et al. Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22, 844 patient years of follow-up from randomised trials. BMJ. 2012;345:e5170. [PMID: 22885395] doi:10.1136/bmj.e5170.
67. Cassese S, Byrne RA, Ndrepepa G, Kufner S, Wiebe J, Repp J, et al. Everolimus-eluting bioresorbable vascular scaffolds versus everolimus-eluting metallic stents: A meta-analysis of randomised controlled trials. Lancet. 2016;387:537-44. [PMID: 26597771] doi:10.1016/S0140-6736(15)00979-4.
68. Lipinski MJ, Escarcega RO, Baker NC, Benn HA, Gaglia MA Jr, Torguson R, et al. Scaffold thrombosis after percutaneous coronary intervention with ABSORB bioresorbable vascular scaffold: A systematic review and meta-analysis. JACC Cardiovasc Interv. 2016;9:12- 24. [PMID: 26762906] doi:10.1016/j.jcin.2015.09.024.
69. Navarese EP, Tandjung K, Claessen B, Andreotti F, Kowalewski M, Kandzari DE, et al. Safety and efficacy outcomes of first and second generation durable polymer drug eluting stents and biodegradable polymer biolimus eluting stents in clinical practice: comprehensive network meta-analysis. BMJ. 2013;347:f6530. [PMID: 24196498] doi:10.1136/bmj.f6530.
70. Palmerini T, Dangas G, Mehran R, Caixeta A, Généreux P, Fahy MP, et al. Predictors and implications of stent thrombosis in non-STsegment elevation acute coronary syndromes: The ACUITY Trial. Circ Cardiovasc Interv. 2011;4:577-84. [PMID: 22028471] doi:10.1161/CIRCINTERVENTIONS.111.963884.
71. Dudek D, Onuma Y, Ormiston JA, Thuesen L, Miquel-Hebert K, Serruys PW. Four-year clinical follow-up of the ABSORB everolimuseluting bioresorbable vascular scaffold in patients with de novo coronary artery disease: The ABSORB trial. EuroIntervention. 2012;7: 1060-1. [PMID: 21959320] doi:10.4244/EIJV7I9A168.
72. Whitbourn RJ. ABSORB EXTEND: An interim report on the 24- month clinical outcomes from the first 250 patients enrolled. J Am Coll Cardiol. 2013;62(Suppl 1):B11. doi:10.1016/j.jacc.2013.08.761.
73. Serruys PW, Onuma Y, Garcia-Garcia HM, Muramatsu T, van Geuns RJ, de Bruyne B, et al. Dynamics of vessel wall changes following the implantation of the Absorb everolimus-eluting bioresorbable vascular scaffold: A multi-imaging modality study at 6, 12, 24 and 36 months. EuroIntervention. 2014;9:1271-84. [PMID: 24291783] doi:10.4244/EIJV9I11A217.
74. Serruys PW, Onuma Y, Dudek D, Smits PC, Koolen J, Chevalier B, et al. Evaluation of the second generation of a bioresorbable everolimus-eluting vascular scaffold for the treatment of de novo coronary artery stenosis: 12-month clinical and imaging outcomes. J Am Coll Cardiol. 2011;58:1578-88. [PMID: 21958884] doi:10.1016/j.jacc.2011.05.050.
75. Claessen BE, Beijk MA, Legrand V, Ruzyllo W, Manari A, Varenne O, et al. Two-year clinical, angiographic, and intravascular ultrasound follow-up of the XIENCE V everolimus-eluting stent in the treatment of patients with de novo native coronary artery lesions: The SPIRIT II trial. Circ Cardiovasc Interv. 2009;2:339-47. [PMID: 20031737] doi:10.1161/CIRCINTERVENTIONS.108.831800.108.831800.
76. Muramatsu T, Onuma Y, Zhang YJ, Bourantas CV, Kharlamov A, Diletti R, et al. Progress in treatment by percutaneous coronary intervention: The stent of the future. Rev Esp Cardiol (Engl Ed). 2013;66: 483-96. [PMID: 24776051] doi:10.1016/j.rec.2012.12.009.
77. Palmerini T, Biondi-Zoccai G, Della Riva D, Mariani A, Sabaté M, Smits PC, et al. Clinical outcomes with bioabsorbable polymer- versus durable polymer-based drug-eluting and bare-metal stents: evidence from a comprehensive network meta-analysis. J Am Coll Cardiol. 2014;63:299-307. [PMID: 24211507] doi:10.1016/j.jacc.2013.09.061.
78. Kang SH, Park KW, Kang DY, Lim WH, Park KT, Han JK, et al. Biodegradable-polymer drug-eluting stents vs. bare metal stents vs. durable-polymer drug-eluting stents: A systematic review and Bayesian approach network meta-analysis. Eur Heart J. 2014;35:1147-58. [PMID: 24459196] doi:10.1093/eurheartj/eht570.
79. Serruys PW, Farooq V, Kalesan B, de Vries T, Buszman P, Linke A, et al. Improved safety and reduction in stent thrombosis associated with biodegradable polymer-based biolimus-eluting stents versus durable polymer-based sirolimus-eluting stents in patients with coronary artery disease: final 5-year report of the LEADERS (Limus Eluted From A Durable Versus ERodable Stent Coating) randomized, noninferiority trial. JACC Cardiovasc Interv. 2013;6:777-89. [PMID: 23968698] doi:10.1016/j.jcin.2013.04.011.
80. Zhang YJ, Iqbal J, Windecker S, Linke A, Antoni D, Sohn HY, et al. Biolimus-eluting stent with biodegradable polymer improves clinical outcomes in patients with acute myocardial infarction. Heart. 2015;101:271-8. [PMID: 25423953] doi:10.1136/heartjnl-2014-306359.
81. Chevalier B, Serruys PW. ABSORB II: A prospective randomized trial of an everolimus-eluting bioresorbable scaffold vs an everolimus-eluting metallic stent in patients with coronary artery disease. Presented at the Transcatheter Cardiovascular Therapeutics (TCT) Meeting 2015, San Francisco, California, 11-15 October 2015. Accessed at www.tctmd.com/txshow.aspx?tid=1663461&id=131613&trid=1659690 on 18 December 2015.